SAN DIEGO, Aug. 2, 2017 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders, announced today
that the company will release financial results for the second
quarter of 2017, after the market close on Wednesday, August 9, 2017.
Brian Lian, Ph.D., Viking's
president and chief executive officer, and Michael Morneau, Viking's chief financial
officer, will host a conference call to discuss financial results
and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, August 9, 2017.
To participate on the conference call, please dial (844)
850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In
addition, following the completion of the call, a telephone replay
will be accessible until August 16,
2017 by dialing (877) 344-7529 from the U.S. or (412)
317-0088 from outside the U.S. and entering conference ID #
10110737. Those interested in listening to the conference call
live via the internet may do so by visiting the Investor Relations
section of Viking's website at www.vikingtherapeutics.com. An
archive of the webcast will be available for 30 days on the
company's website at www.vikingtherapeutics.com.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development of novel, first-in-class or
best-in-class therapies for metabolic and endocrine
disorders. The company's research and development activities
leverage its expertise in metabolism to develop innovative
therapeutics designed to improve patients' lives. Viking has
exclusive worldwide rights to a portfolio of five therapeutic
programs in clinical trials or preclinical studies, which are based
on small molecules licensed from Ligand Pharmaceuticals
Incorporated. The company's clinical programs include VK5211,
an orally available, non-steroidal selective androgen receptor
modulator, or SARM, in Phase 2 development for the treatment and
prevention of lean body mass loss in patients who have undergone
hip fracture surgery, VK2809, a small molecule thyroid beta agonist
in Phase 2 development for hypercholesterolemia and fatty liver
disease, and VK0612, a first-in-class, orally available drug
candidate in Phase 2 development for type 2 diabetes. Viking is
also developing novel and selective agonists of the thyroid beta
receptor for GSD Ia and X-linked adrenoleukodystrophy, as well as
two earlier-stage programs targeting metabolic diseases and
anemia.
Follow Viking on Twitter @Viking_VKTX.
Forward-Looking Statements
This press release contains forward-looking statements
regarding Viking Therapeutics, including statements about Viking's
expectations regarding its development activities, timelines and
milestones, as well as the company's goals and plans regarding
VK5211 and VK5211's prospects. Forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially and reported results should not be considered
as an indication of future performance. These risks and
uncertainties include, but are not limited to: risks associated
with the success, cost and timing of Viking's product candidate
development activities and clinical trials, including those for
VK5211 and VK2809; risks that prior clinical and pre-clinical
results may not be replicated; and risks regarding regulatory
requirements, among others. These forward-looking statements speak
only as of the date hereof. Viking disclaims any obligation to
update these forward-looking statements.
View original
content:http://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-second-quarter-2017-after-market-close-on-august-9-2017-300497664.html
SOURCE Viking Therapeutics, Inc.